This article is more than 5 years old. Information may no longer be current.
Treating CTO with BVS safe, effective if proper procedures followed
Click Here to Manage Email Alerts
In patients with chronic total occlusion lesions, treatment with a bioresorbable vascular scaffold appears to be feasible and safe, according to recent findings.
In the study, researchers retrospectively assessed 65 consecutive patients with a CTO (mean age, 61 years; 89% men; 40% with diabetes) who were treated with a BVS (Absorb, Abbott Vascular) as part of a multicenter registry between September 2012 and November 2015. The researchers designated target lesion failure as the study’s primary endpoint. TLF was defined as a composite of cardiac death, target vessel MI and clinically driven target lesion revascularization. The patient population had a mean ejection fraction of 57.7 ± 10.8%, a mean reference vessel diameter of 3 ± 0.4 mm and a mean CTO lesion length of 20.2 ± 3 mm.
The researchers found that, for each patient, a mean of 1.8 ± 0.7 BVS were utilized. The mean diameter of the BVS was 3 ± 0.4 mm and the total length was 47.6 ± 19.9 mm. In all cases, postdilation with noncompliant balloons (mean diameter, 3.3 ± 0.3 mm) was performed at high pressures (18.6 ± 5.3 atmospheres). All patients were assessed with either IVUS (n = 34) or OCT (n = 31). The median follow-up was 453 days, and in 22 patients (33.8%), follow-up angiography was performed.
No in-hospital adverse events were recorded. During follow-up, no cases of TLF occurred. There were four cases of target vessel revascularization during follow-up. No cases of significant intra-scaffold restenosis requiring revascularization were reported, either clinically or on angiography. No cases of definite/probable stent thrombosis occurred. Premature discontinuation of dual antiplatelet therapy occurred in one patient within 12 months, and this discontinuation was due to a gastric ulcer.
“There were no occurrences of [TLF], defined as a composite of cardiac death, target vessel [MI], clinically driven [TLR], and scaffold thrombosis after BVS implantation for [CTOs],” the researchers wrote. “Intravascular imaging-guided lesion preparation and postdilatation are recommended to obtain the best possible final result in BVS implantation for [CTOs].” – by Jennifer Byrne
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts